Currently, there are 696.83M common shares owned by the public and among those 75.96M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -11.49% and -44.34% over the past three months. IBRX shares are trading 11.33% year to date (YTD), with the 12-month market performance down to -37.36% lower. It has a 12-month low price of $2.28 and touched a high of $10.53 over the same period. IBRX has an average intraday trading volume of 6.39 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.04%, -5.23%, and -36.59% respectively.
Institutional ownership of ImmunityBio Inc (NASDAQ: IBRX) shares accounts for 11.58% of the company’s 696.83M shares outstanding.
It has a market capitalization of $2.08B and a beta (3y monthly) value of 0.71. The earnings-per-share (ttm) stands at -$0.89. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.49% over the week and 9.73% over the month.
Earnings per share for the fiscal year are expected to decrease by -8.06%, and 38.81% over the next financial year.
Looking at the support for the IBRX, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on January 10, 2025, with the firm’s price target at $6. Piper Sandler coverage for the ImmunityBio Inc (IBRX) stock in a research note released on May 12, 2023 offered a Neutral rating with a price target of $4.
